Abstract 3247
Background
The optimal treatment for locally advanced borderline-resectable squamous cell carcinoma (SCC) of the oesophagus is unclear. This phase II trial assessed the safety and efficacy of paclitaxel in combination with cisplatin and 5-fluorouracil (TPF) induction chemotherapy and subsequent surgery for locally advanced borderline-resectable esophageal SCC (NCT02976909).
Methods
Patients with clinical T4 and/or bulky lymphadenopathy that may invade nearby organs were eligible. Treatment started with 2 to 4 cycles of TPF induction chemotherapy (paclitaxel 135mg/m2 on day 1, cisplatin 75mg/m2 on Day 1; 5-fluorouracil 4g/m2 for 120 hours continuous infusion from Day 1 to Day 5), followed by surgery if resectable, or by radical concurrent chemoradiotherapy if unresectable. The primary endpoint was pathologically proven complete resection (R0) rate.
Results
From November 2016 to December 2018, 47 patients were enrolled. After 2 to 4 cycles TPF chemotherapy, surgery was performed in 27 patients (57.4%), 10 (21.3%) patients received radical concurrent chemoradiotherapy. R0 resection was confirmed in 25 patients (53.2%). Pathologic complete response after chemotherapy was confirmed in 4 patients (8.5%). During chemotherapy, the most common grade 3 or 4 toxicities were neutropenia (29.8%), leucopenia (21.3%), febrile neutropenia (4.3%) and stomatitis (4.3%). No serious postoperative complications were observed in patients undergoing surgery.
Conclusions
TPF induction chemotherapy followed by surgery as a multidisciplinary treatment strategy showed promising signs of tolerability and short-term efficacy in patients with locally advanced borderline-resectable esophageal SCC. Long-term survival is still being followed up.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yuhong Li.
Funding
Guangdong Esophageal Cancer institute.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2078 - Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2+) cholangiocarcinoma (CCA) treated with pemigatinib in the fight-202 trial
Presenter: Antoine Hollebecque
Session: Poster Display session 2
Resources:
Abstract
3879 - Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications
Presenter: Michele Droz Dit Busset
Session: Poster Display session 2
Resources:
Abstract
4679 - It’s Not Only About Weight Loss: Tackling Pancreatic Cancer-Associated Cachexia
Presenter: Ana Leonor Matos
Session: Poster Display session 2
Resources:
Abstract
2276 - Frequency and clinicopathological characteristics of biliary tract carcinomas harboring the FGFR2-fusion gene: a prospective observational study (PRELUDE study)
Presenter: Masafumi Ikeda
Session: Poster Display session 2
Resources:
Abstract
2773 - Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7.1) in a randomized Phase II study
Presenter: Ulrich-Frank Pape
Session: Poster Display session 2
Resources:
Abstract
4479 - Capecitabine +Best supportive care (BSC) or Erlotinib +BSC has Overall survival (OS) benefit over BSC alone in unresectable/metastatic Gall bladder cancer(GBC) patients with ECOG PS-III. Results from a phase II Randomised controlled trial (RCT)
Presenter: Babita Kataria
Session: Poster Display session 2
Resources:
Abstract
4843 - FGFR2 fusions and its effect of patient (pt) outcomes in intrahepatic cholangiocarcinoma (iCCA)
Presenter: Daniel Almquist
Session: Poster Display session 2
Resources:
Abstract
2324 - The Clinical Outcomes of Systemic Chemotherapy in Patients with Unresectable or Metastatic Combined Hepatocellular-cholangiocarcinoma (HCC-CCA): Retrospective Study of 120 Patients
Presenter: Eojin Kim
Session: Poster Display session 2
Resources:
Abstract
3678 - High PD-L1 expression is associated with treatment response to pembrolizumab in patients with advanced biliary tract cancer.
Presenter: Gilhyang Kim
Session: Poster Display session 2
Resources:
Abstract
3901 - Genomic profiling in Chinese biliary tract cancer patients with PI3K/AKT/mTOR pathway and RAS gene mutations
Presenter: Jingyu Cao
Session: Poster Display session 2
Resources:
Abstract